1. Introduction {#sec1}
===============

Systemic delivery of cytokines could be an innovative treatment for genetic diseases characterized by failure in cytokine pathways [@bib1]. However, this treatment could be cumbersome for many reasons. They include i) the lack of industrial interest to develop pharmaceutical formulations of a cytokine that should be available only for a limited number of patients, ii) the demanding compliance because of the parenteral route of administration, and iii) the difficulty to adjust the dose according to the real status of the disease.

Long-lasting delivery of a cytokine through a regulated biological system would be ideal to prevail over these inconveniences. Several cytokines are released by cells originating from the mesenchymal stem cell family [@bib2] under the control of local and systemic regulating pathways, which makes this cell family a superlative tool if transplanted in vivo. However, although intense research is ongoing for the development of transplant procedures for mesenchymal stem cells, so far, the experimental efforts did not lead to satisfactory engraftment [@bib3; @bib4], therefore this option remains currently unfeasible.

Some cytokines are membrane-bound proteins that require cell--cell contact or ectodomain shedding to exert their action. For instance, the Receptor Activator of Nuclear Factor-κB transcription factor Ligand (RANKL) is a trimeric cytokine belonging to the Tumor Necrosis Factor (TNF) family [@bib5], which exhibits potent osteoclastogenic properties [@bib6]. In bone, it is expressed by the osteogenic lineage [@bib7] as a surface protein and is known to trigger osteoclast formation upon exposure of bone marrow mononuclear cells to the Macrophage-Colony Stimulating Factor (M-CSF) [@bib8], another essential cytokine that promotes proliferation of osteoclast precursors [@bib9], and sensitizes them to RANKL inducing the expression of the RANKL receptor, RANK [@bib10]. RANKL has also emerged to play many roles in other organs [@bib11]. It is produced by T-cells in response to inflammatory stimuli, enhancing osteoclast activity in inflammatory diseases such as the rheumatoid arthritis [@bib12; @bib13]. It also regulates mammary gland development [@bib14] and is involved in mammary gland tumorigenesis [@bib15]. Finally, RANKL has been found to be involved in the control of body temperature [@bib16], therefore it is now accepted that it has multifunctional roles in a variety of pathophysiological conditions. The extracellular active domain of RANKL can be enzymatically cleaved, affecting target cells in a paracrine fashion [@bib17]. Therefore, it is a translational challenge to implement soluble (s)RANKL shedding in order to make its effects systemic.

A severe genetic pathology, known to depend on mutations of the *TNFSF11* gene encoding RANKL [@bib18], belongs to the autosomal recessive osteopetrosis disease family, a bone disorder characterized by lack of osteoclast bone resorption [@bib1] causing lethal skeletal, hematological and neuronal failures. Several subtypes of osteopetrosis are known, classified as osteoclast-rich and osteoclast-poor [@bib19]. Osteoclast-rich osteopetroses present with fully differentiated but non-functional osteoclasts due to mutations of genes involved in the mechanism of bone resorption [@bib19]. In osteoclast-poor osteopetroses, osteoclasts do not form because of loss-of-function mutations of genes involved in osteoclastogenesis, such as *TNFSF11*, encoding RANKL [@bib18], and *TNFRSF11A*, encoding its receptor RANK [@bib20]. While RANK is an osteoclast lineage intrinsic protein [@bib21], RANKL ligand is expressed by other cell types [@bib7; @bib12; @bib13; @bib22], therefore osteopetrosis induced by its deficiency is not osteoclast-autonomous [@bib18].

Osteoclasts belong to the myeloid lineage [@bib23], therefore most forms of osteopetrosis are treated by hematopoietic stem cell transplantation, with increasing success of engraftments over the last decade even for mismatched donors [@bib24]. Unfortunately, given that RANKL deficiency is caused by an osteoclast non-autonomous defect, this treatment regimen cannot be applied to this form of osteopetrosis and new therapies need to be developed.

Mouse models of RANKL deficiency were generated in 1999 and 2000 [@bib25; @bib26]. These models have been fully characterized and shown to respond to RANKL by a recovery of osteoclastogenesis [@bib25]. Lo Iacono et al. [@bib27] have recently demonstrated that infusion of RANKL could indeed partially rescue the osteopetrotic phenotype of RANKL-deficient mice and hypothesized that treatment of humans with the soluble cytokine could be feasible [@bib1]. However, there are several pitfalls in this treatment regimen [@bib1], including RANKL accumulation over time inducing severe overdose problems, which make it difficult to currently predict a translational impact of this study.

RANKL deficiency is a paradigm of a disease due to lack of a cytokine. Therefore, we believe that this model is ideal to investigate new biotechnological approaches to overcome, in the future, the above-mentioned pitfalls for the treatment of these types of diseases. However, before setting a specific translational protocol, we need a proof-of-principle that such an approach could work in an appropriate animal model. The *tnfsf11* knockout (KO) mice have the unique feature to generate no osteoclasts at all [@bib25; @bib26], therefore any positive effect induced by innovative methods of RANKL delivery could be easily validated by the appearance of cells of the osteoclast lineage, whose detection can straightforwardly be obtained by histochemical staining of the osteoclast-specific marker Tartrate-Resistant Acid Phosphatase (TRAcP) [@bib28].

The prototype of our biotechnological device is the diffusion chamber, which is a well-established tool to study several in vivo biological processes, also in bone biology. It has largely been used in several studies to investigate in vivo osteoblast and osteoclast functions and regulation of bone formation and bone resorption [@bib29; @bib30]. Moreover, it is suitable for studies concerning bone tissue engineering [@bib31], and for supplying hormonal factors to deficient backgrounds [@bib32].

Diffusion chambers are made by overlapping plexiglas rings and porous durapore membranes (pore diameter 0.22 μm), that delimit an internal space in which cells grow. The durapore membranes provide high flow rates and throughput, low extractable and broad chemical compatibility. Cells are inoculated in the chamber and, through their pores, durapore membranes allow diffusion of water, solutes and macromolecules into the microenvironment, but prevent migration of cells outside the chamber, therefore, in vivo, cells do not interact with the host immune system and do not elicit cell-mediated immune response.

The aim of this study was to exploit the *tnfsf11* KO mice to test the principle that systemic delivery of a membrane-bound curative cytokine is feasible using diffusion chambers carrying RANKL-producing cells enzymatically manipulated to promote the active ectodomain shedding. In vivo implant of our diffusion chambers in *tnfsf11* KO mice demonstrated that, by our biotechnological approach, sRANKL can be released by cells into the circulation and induce systemic effects, as assessed by the appearance of functional osteoclasts in the bone of implanted mice.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

Procedures involving animal care were conducted in conformity with national and international laws and policies (EEC Council Directive 86/609, OJ L 358, 1, Dec. 12, 1987; Italian Legislative Decree (Gu n. 61, 14/03/2014); NIH guide for the Care and Use of Laboratory Animals, NIH Publication No. 85-23, 1985), and were approved by the Institutional Review Board of the University of L\'Aquila. At the end of the experiments, mice were sacrificed by CO~2~ inhalation. Wild type (WT) mice used for primary cell cultures were on CD1 background, while *tnfsf11* KO mice and their WT counterpart used for in vivo implants were on C57BL6/CD1 background.

2.2. Cell cultures {#sec2.2}
------------------

Mouse osteoblast cultures were derived from 8-to-10 day-old mice. Briefly, calvariae were dissected and sequentially digested with 1 mg/ml Clostridium histolyticum type IV collagenase (Sigma) and 0.025% trypsin (Becton Dickinson) in Hank\'s buffered solution. Cells from second and third digestions were grown in Dulbecco\'s modified Minimum Essential Medium (DMEM) with antibiotics and 10% Fetal Bovine Serum (FBS). At confluence, cells were released by trypsin procedure, counted and plated in appropriate vessels for further experiments. The osteoblast phenotype was evaluated by histochemical analysis of ALP activity, using reagents and protocols from the Sigma--Aldrich kit 104-LS. Mineralization assay was performed in osteoblasts cultured for 21 days in osteogenic medium \[DMEM supplemented with FBS (10%), β-glycerophosphate (5 m[m]{.smallcaps}) and ascorbic acid (50 μg/ml)\], and evidenced by alizarin red in 4% formalin-fixed cell cultures. When required, osteoblasts were treated with human recombinant ParaThyroid Hormone 1-34 \[hrPTH(1-34)\] (Sigma--Aldrich, cat \# P3796).

Bone marrow stromal cells were the adherent cells after 48 h from flashing out and culturing the total bone marrow cells from long bones of 8-to-10 days old mice.

Bone marrow mesenchymal stem cells were obtained by immunomagnetic sorting of mouse bone marrow cells, using antibodies recognizing the specific markers STRO-1 and c-kit (Myilteny Biotech).

2.3. Cell culture support {#sec2.3}
-------------------------

Hydroxyapatite (HA) intact granulates and tridimensional (3D) HA scaffolds (Scaffdex CellCeram™) were purchased from Sigma Aldrich (cat \# 289396 and cat \# Z682012, respectively). They were used to culture primary osteoblasts obtained as described above, according to the manufacturer\'s instruction.

2.4. Diffusion chambers {#sec2.4}
-----------------------

Diffusion chamber kits (Millipore) were used for both in vitro and in vivo experiments, according to the manufacturer\'s instructions. They are made by two Plexiglas^®^ Rings with 0.59 mm hole (Millipore cat \# PR0001401) sealed using 13 mm durapore membrane filters, 0.22 micron pore size (Millipore cat \# GSWP 013 00), glued altogether with Membrane Filter Cement (Millipore cat \# XX70 000 72). Primary mouse calvarial osteoblasts were inoculated, with or without 3D HA, into the chambers, which were then sealed as described. For in vivo studies, the diffusion chambers were implanted in the abdomen or in the flank of mice under deep anesthesia (2.5 mg Ketamine + 0.5 mg Xilazine in 100 μl saline solution/mouse).

2.5. sRANKL and osteoprotegerin (OPG) {#sec2.5}
-------------------------------------

sRANKL and OPG were quantified in cell conditioned media using the R&D System ELISA kits, MTR00 and MOP00 respectively, according to the manufacturer\'s instructions. Titration of free sRANKL was computed by the difference between equivalent weight of sRANKL and OPG obtained from ELISA, assuming 1:1 as reactive normality of sRANKL:OPG ratio.

Human recombinant sRANKL (Peprotech, cat \# 310-01) was used for the in vitro osteoclastogenic assay.

2.6. Western blot and RT-PCR {#sec2.6}
----------------------------

For Western blots, reagents were from Sigma Aldrich. Conditioned media proteins resolved on a 12% SDS-PAGE were trans-blotted to nitrocellulose membranes and probed with the primary RANKL antibody (R&D, cat \# AF462, 1:200) overnight at 4 °C, washed and incubated with the HRP-conjugated secondary antibody for 1 h at room temperature. Protein bands were revealed by enhanced chemiluminescence (ECL).

For Real-time RT-PCR, reagents were from Invitrogen. Total RNA was extracted using the Trizol^®^, then 1 μg was reverse transcribed and the equivalent of 0.1 μg was employed for the PCR reactions using the Brilliant^®^ SYBR^®^ Green QPCR master mix, using primer pairs specific for murine RANKL and OPG.

2.7. Enzymatic activity and immobilization {#sec2.7}
------------------------------------------

MMP14, MMP7 and TACE catalytic domains were purchased from Biomol. Catalytic activity was monitored by quenched fluorescent peptide substrate MCA (Biomol), according to the manufacturer\'s instructions. Immobilization procedures were performed with glutaraldehyde (10% v/v) (Sigma Aldrich).

2.8. Statistics {#sec2.8}
---------------

Data are expressed as mean ± standard deviation (s.d.). Statistical analysis was performed by the unpaired Student\'s *t* test or by the one-way Analysis of Variance (ANOVA). A p value \<0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Identification of cell type and culture condition to supply sRANKL {#sec3.1}
-----------------------------------------------------------------------

In the perspective of a translational application, one of the main strength of our approach could be the use of cells biologically expressing RANKL in a regulated fashion. This would offer the advantage of a "natural" control of the release of sRANKL which is not achievable using transfected cells or infusion of the cytokine. Therefore, the first part of the study had the aim to identify the best cell type and culture conditions to supply sRANKL.

To this purpose, we have tested mouse primary calvarial osteoblasts, bone marrow stromal cells and bone marrow mesenchymal stem cells. First, we evaluated different osteoblast densities to obtain both long-term survival and optimal sRANKL release in conditioned medium. We noted that the best cell density was 300,000 cells/cm^2^, with which the evaluation of sRANKL by ELISA every five days showed a time-dependent free sRANKL accumulation in the culture medium ([Fig. 1](#fig1){ref-type="fig"}A). In the same culture conditions, bone marrow stromal cells showed lower release of sRANKL than osteoblasts ([Fig. 1](#fig1){ref-type="fig"}B). In addition, the assessment of cell viability demonstrated reduced cell survival with time. Therefore, we concluded that this cell type is not suitable for our research. We then evaluated bone marrow mesenchymal stem cells. As shown in [Fig. 1](#fig1){ref-type="fig"}C, the sRANKL yield in these cultures was comparable to that of osteoblasts. We also isolated primary osteocytes which are considered the bone cells with the highest RANKL expression [@bib33]. However, isolation procedure was time-consuming and proliferation rate of these cells in culture was low, making them unsuitable for a large-scale use. Therefore, because calvarial osteoblasts were more readily available and easy to handle, we considered them as the best biological sRANKL source suitable for our purpose. RT-PCR and Western blot analyses confirmed that these cells expressed RANKL and OPG mRNAs ([Fig. 1](#fig1){ref-type="fig"}D) and released sRANKL into the medium ([Fig. 1](#fig1){ref-type="fig"}E), therefore we decided to use them for improving sRANKL shedding.

3.2. Osteoblast cultures on hydroxyapatite supports {#sec3.2}
---------------------------------------------------

We evaluated sRANKL shedding in mouse primary calvarial osteoblasts grown on biocompatible supports. The purpose was to maintain cells in a situation closer to their in vivo setting and provide a substrate compatible with their long-term survival and enzymatic manipulation (see below). We used both granular hydroxyapatite (HA) and 3D HA scaffolds ([Fig. 2](#fig2){ref-type="fig"}A--D). Evaluation of conditioned media showed a higher spontaneous sRANKL release by osteoblasts cultured on HA supports than by cells grown on plastic dishes, with the 3D HA scaffolds better performing compared to the other conditions ([Fig. 2](#fig2){ref-type="fig"}E).

3.3. Regulated expression of RANKL {#sec3.3}
----------------------------------

Since in vivo RANKL production is regulated by PTH, which is elevated in osteopetrosis, we assessed whether in our experimental conditions this hormone could improve the rate of sRANKL released by the osteoblasts. Consistent with this knowledge, we observed that treatment of our cell cultures with 10^−8^ [m]{.smallcaps} human recombinant (hr)PTH(1-34) increased the free sRANKL concentration by ∼2.5 fold compared to basal conditions ([Fig. 2](#fig2){ref-type="fig"}F), suggesting that in vivo the hormone could regulate the yield of sRANKL from the implanted cells. Taken together, these results demonstrate that we have obtained a suitable cell source of sRANKL which can be used for our biotechnological approach in a manner physiologically regulated by hormonal factors, such as the PTH.

3.4. Enhancement of sRANKL shedding by enzymatic manipulation {#sec3.4}
-------------------------------------------------------------

Since cells retain RANKL in large part as membrane-bound protein, this could represent an important drawback in our translational application, which instead requires systemic delivery. Enzymatic ectodomain shedding induces the release of the active extracellular domain of membrane-bound cytokines, which become soluble and can circulate. MMP14 is a metalloproteinase known to have RANKL ectodomain shedding properties [@bib34]. It is commercially available as active catalytic domain corresponding to the naturally-occurring active form of MMP14 which lacks the C-terminal hemopexin domain [@bib35]. To initially test whether proteolytic shedding of sRANKL is feasible, we treated mouse primary calvarial osteoblasts with vehicle or with 50--1000 ng/ml MMP14 for 5 days. Morphological analysis of cell cultures showed normal cell viability and slight concentration-dependent decrease of Alkaline Phosphatase (ALP) histochemical activity by treatment with MMP14 ([Fig. 3](#fig3){ref-type="fig"}A). ELISA assay demonstrated a concentration-dependent increase of free sRANKL in conditioned media from cells treated with MMP14 versus control cultures ([Fig. 3](#fig3){ref-type="fig"}B). Furthermore, MMP14 did not impair osteoblast activity as demonstrated by normal mineralization of extracellular matrix nodules ([Fig. 3](#fig3){ref-type="fig"}C). Taken together, these results suggest that treatment with MMP14 is safe and effective in shedding sRANKL from its membrane-bound form even in long-term treatments.

Nevertheless, for our application, it is imperative to demonstrate that the enzyme could remain stable in long-terms, to allow its use also in in vivo experiments. To this aim we evaluated MMP14 catalytic activity using the fluorescent substrate (7-Methoxycoumarin-4-yl) acetyl-Pro-Leu-Gly-Leu-\[3-(2,4-dinitrofenil)-L-2,3-diaminoproprionyl\]-Ala-Arg-NH~2~ (MCA), keeping the enzyme at 37 °C and 5% CO~2~ atmosphere for 15 days. The results showed that in the timeframe of our experiment, the enzyme retained its catalytic ability intact ([Fig. 3](#fig3){ref-type="fig"}D).

Other proteolytic enzymes, including MMP7 [@bib36] and TNF-α Converting Enzyme (TACE) [@bib37] also display RANKL shedding activity. Hence, we next tested whether there could be any advantage in using these two enzymes instead of MMP14. [Fig. 3](#fig3){ref-type="fig"}E shows that MMP14, MMP7 and TACE had similar RANKL shedding activity. Thus, we decided to keep with MMP14.

3.5. MMP14 immobilization {#sec3.5}
-------------------------

To the purpose of our study, in vivo systemic effects of the MMP14 are not desirable as it could affect various biological pathways if released into the circulation. To sort out this problem, we tested the possibility to immobilize the recombinant catalytic domain of MMP14 on substrate, which will locally subject the cells to the continuous action of the enzyme, preventing its egress into the circulation. For the first evaluation, we absorbed MMP14 on Glutatione-S-Transferase (GST)-agarose beads using glutaraldehyde. This aldehyde has the ability to form covalent bonds between two molecules, interacting with the hydroxylic groups of serine/tyrosine and causing molecule immobilization on substrate [@bib38]. Assessment of degradation of the fluorescent peptide MCA showed that in this condition the catalytic activity was low ([Fig. 4](#fig4){ref-type="fig"}A). We hypothesized that this inconvenience could arise from chemical alteration of the enzyme catalytic site caused by glutaraldehyde cross-links. We therefore decided to protect this site by pre-incubation for 2 h with MCA (20 and 50 μ[m]{.smallcaps}), namely the same substrate used for determining the MMP14 catalytic activity. We then washed out the MCA and incubated again the GST-agarose bead-immobilized enzyme with MCA for re-testing the hydrolytic activity. We observed that indeed this pre-incubation with MCA was effective, resulting in a concentration-dependent protection capacity of the substrate ([Fig. 4](#fig4){ref-type="fig"}A).

3.6. Enzymatic shedding of sRANKL from cells cultured on 3D HA scaffolds {#sec3.6}
------------------------------------------------------------------------

To exploit the sRANKL shedding ability of MMP14, we engineered the 3D HA scaffolds with MMP14, using the glutaraldehyde treatment. We used different combinations of glutaraldehyde (10--20%) and MCA (1--2 μg/ml), in order to improve the immobilization efficiency. These combinations were successful but we were unable to obtain an enzymatic efficiency of functionalized scaffolds greater than ∼50% compared to soluble MMP14 ([Fig. 4](#fig4){ref-type="fig"}B).

We therefore decided to test whether even 50% preserved catalytic activity could suffice to increase sRANKL release from cells. We cultured mouse calvarial osteoblasts on 3D HA scaffolds functionalized with MMP14 as described above. ELISA evaluation of conditioned media showed that the yield of sRANKL from osteoblasts cultured on MMP14-functionalized scaffold was higher than in conditioned media from osteoblasts cultured on intact scaffold ([Fig. 4](#fig4){ref-type="fig"}C), confirming that MMP14 was correctly immobilized and effective in shedding the RANKL active domain from the membrane bound RANKL. We evaluated this enzymatic ability up to 30 days of culture and observed that it was maintained intact for the timeframe of this observation.

3.7. Osteoclastogenesis assay {#sec3.7}
-----------------------------

The average concentration of sRANKL achieved in these experimental conditions at 5 days of culture was greater than 2 ng/ml. To verify whether this concentration was suitable to enhance osteoclast formation, we performed an osteoclastogenesis assay in the presence of increasing concentrations of commercially available sRANKL. In our culture conditions, we observed that 1 ng/ml sRANKL induced osteoclast formation near the plateau level ([Fig. 4](#fig4){ref-type="fig"}D), suggesting that with our strategy we achieved sRANKL levels sufficient to support osteoclast formation in vitro.

3.8. In vivo implants {#sec3.8}
---------------------

To assess the feasibility of our strategy in vivo, we first performed preliminary tests to set up the conditions to implant the diffusion chambers in mice. We implanted diffusion chambers containing 1,000,000 mouse primary calvarial osteoblasts/chamber without scaffold, subcutaneously, in the abdomen of 30-days old wild-type (WT) C57BL6 mice and monitored animals for 3 weeks. In this timeframe, we did not observe any sign of distress. We euthanized the mice and gathered the diffusion chambers. We did not observe obvious internal damages or signs of inflammation at autopsy near the area of implant. Diffusion chambers contained viable cells, which resulted positive to the osteoblast marker, ALP ([Fig. 5](#fig5){ref-type="fig"}A).

We then tested the implant of diffusion chambers containing MMP14-functionalised scaffold harboring osteoblasts in younger WT C57BL6 mice (10--20 days of age). We made this choice in order to verify that no damage occurred due to the presence of the scaffold in the diffusion chamber, and to set up the implant procedure as early as possible. We observed that the hold of the diffusion chambers in mice younger than 21 days was problematic due to skin damage at the implant site. However, in mice in which the diffusion chambers were successfully engrafted, after 3 weeks from implant they contained viable cells on scaffold. These results warn about the age of animals to be implanted, but confirm that the scaffold and its enzymatic functionalization by MMP14 causes no harm.

Having established that implanted mice cannot be younger than 21 days, we tested *tnfsf11* KO mice at this age, implanting them with diffusion chambers containing MMP14 functionalized scaffold harboring osteoblasts. Unfortunately, due to their body size much lower than the WT counterpart, only some *tnfsf11* KO mice succeeded to retain the diffusion chambers. At the end of the experiment, their body weight was similar to that of the control *tnfsf11* KO mice ([Fig. 5](#fig5){ref-type="fig"}B). However, the implanted mice were more active and lively while the untreated *tnfsf11* KO counterparts were generally apathetic. Mice were euthanized between 15 and 30 days from the implants (age 36--51 days) and long bones were histochemically evaluated for the osteoclast-specific enzyme TRAcP. We noticed the presence of small TRAcP-positive cells, presumably mononuclear precursors belonging to the osteoclast lineage, in tibias of all animals of the implanted group. TRAcP staining was instead totally absent in all control animals histologically evaluated in the study ([Fig. 5](#fig5){ref-type="fig"}C,D). Furthermore, in some *tnfsf11* KO animals of this group we experienced again the loss of diffusion chambers between 3 and 14 days from surgery. Therefore, the success of retaining of the implant in the abdomen of 21 days-old *tnfsf11* KO mice was still problematic.

To overcome this problem we grew the *tnfsf11* KO mice to adulthood through the administration of a soft diet, which prevented the insufficient nutrition due to the lack of tooth eruption [@bib25; @bib26]. This allowed us to implant *tnfsf11* KO mice with 1 diffusion chamber between 36 and 42 days of life. Mice did not show any distress due to the implant. However, they did not exhibit increase of their weight compared to control mice ([Fig. 6](#fig6){ref-type="fig"}A). They were sacrificed after one month from implant. Notably, histochemical evaluation of tibias confirmed the appearance of TRAcP-positive cells in the implanted mice compared to controls ([Fig. 6](#fig6){ref-type="fig"}B,C).

In further groups of *tnfsf11* KO we implanted 1 or 2 diffusion chambers at 36 days of life. After 1 month (age 72 days) they were replaced with two fresh diffusion chambers and mice were sacrificed 1 month later (age 102 days). While mice implanted with total 3 diffusion chambers still did not show any growth improvement, those implanted with 4 diffusion chambers exhibited an increase of body weight. Moreover, in histological sections, we observed TRAcP-positive cells ([Fig. 6](#fig6){ref-type="fig"}D,E) that, in the group implanted with 4 diffusion chambers, adhered to the bone surface and were morphologically very similar to mature osteoclasts ([Fig. 6](#fig6){ref-type="fig"}E). In addition, histochemical staining for TRAcP and nuclear co-staining with DAPI, unraveled that these cells were multinucleated ([Fig. 6](#fig6){ref-type="fig"}F). These data were confirmed quantitatively. In fact, in the group implanted with 4 diffusion chambers we observed a higher number of TRAcP-positive cells ([Fig. 6](#fig6){ref-type="fig"}G) and a greater TRAcP-positive cell area ([Fig. 6](#fig6){ref-type="fig"}H), suggesting that, with this strategy, we obtained full osteoclastogenesis.

Next, we assessed in histological sections whether the newly formed osteoclasts were functional. To this end, we measured the eroded bone surface underneath the TRAcP-positive cells and observed that, at variance with non-implanted *tnfsf11* KO mice, in which there were no osteoclasts and eroded surface, in the 4 diffusion chambers implanted mice eroded surface underneath the TRAcP-positive multinuclear cells was quantifiable ([Fig. 7](#fig7){ref-type="fig"}A). Finally, to assess whether this level of bone resorption could induce any benefit on the structure of the bone, we measured the proximal tibia trabecular bone volume over total tissue volume and observed a significant decrease compared to the non-implanted *tnfsf11* KO mice ([Fig. 7](#fig7){ref-type="fig"}B). Taken together, these results demonstrated that with the implant of 4 diffusion chambers total, we obtained functional osteoclasts capable of eroding the bone surface and reduce the trabecular bone mass in tibias.

Finally, to assess whether our strategy could induce adverse effects, we performed histological evaluation of lungs, which were reported to undergo worsening of lymphoid infiltrations in *tnfsf11* KO mice treated with sRANKL [@bib27]. Our analysis demonstrated no changes in number and size of lymphoid aggregates in implanted KO mice compared to their non-implanted counterpart ([Fig. 8](#fig8){ref-type="fig"}), suggesting that at least this variable is not aggravated by our treatment.

4. Discussion {#sec4}
=============

In this study, we were able to demonstrate that a biotechnological approach allows the release of the active ectodomain of membrane-bound RANKL from mouse primary calvarial osteoblasts in an amount that induced the formation of functional osteoclasts. We showed that, among the RANKL cell sources tested, calvarial osteoblasts were the most efficient and easy to handle. Bone marrow stromal cells produced about half of the sRANKL amount produced by osteoblasts, while bone marrow mesenchymal stem cells, although as efficient as osteoblasts in sRANKL yield, required time and effort to be isolated. Likewise, osteocytes needed time-consuming isolation procedures and showed low yield and slow proliferation rate in culture, therefore, although they are great RANKL producers [@bib33], they are currently not suitable for biotechnological purposes.

We also demonstrated that substrate and culture conditions are important factors to improve the yield of sRANKL. In fact, HA supports were more efficient than plastic dishes to stimulate cytokine release by osteoblasts, and 3D cultures on HA scaffolds were more efficient than 2D cultures on HA granulate. HA is a natural substrate for osteoblasts that could contribute to create a more physiologic environment. In addition, in vivo osteoblasts sit on 3D bone structures, therefore, not surprisingly, the 3D HA scaffolds supported the best yield of sRANKL, that was double compared to osteoblasts cultured on plastic, and 1.5 fold more than in osteoblasts cultured on HA granulate. This was a fortunate circumstance because it allowed us to immobilize a RANKL-shedding enzyme on 3D scaffolds and improve the efficiency of sRANKL discharge in the conditioned medium.

In fact, the active domain of RANKL is displayed extracellularly and, in certain circumstances, it can be released in the microenvironment through enzymatic cleavage [@bib39]. RANKL deficiency induces a systemic disease, which cannot be cured by local procedures. Major effects of RANKL in bone are exerted in a paracrine manner, and the bound of the cytokine to the osteoblast plasma membrane ensures a controlled regulatory activity on osteoclast precursors through cell-to-cell contact [@bib40]. Unfortunately, this physiologic circumstance limits the use of cell implants when a membrane-bound cytokine is desirable to exert systemic effects. We overwhelmed this inconvenience testing various RANKL-shedding enzymes, MMP14 [@bib34], MMP7 [@bib36] and TACE [@bib37], which were equally efficient in releasing the RANKL ectodomain in the conditioned medium. We focused on MMP14 and were able to immobilize its commercially available catalytic domain on the 3D HA scaffolds. The MMP14 enzymatic activity was stable over time and enabled a significant enhancement of sRANKL shedding compared to intact scaffolds. Altogether, these maneuvers resulted in a sRANKL yield sufficient to induce osteoclastogenesis in vitro and in vivo.

To investigate the impact of our biotechnological device in vivo, we took advantage of the *tnfsf11* KO mouse model that is characterized by the total absence of the osteoclast lineage and by complete TRAcP negativity in histological sections. We observed that diffusion chambers, inoculated with osteoblasts on MMP14-engineered 3D HA scaffolds and implanted in vivo in *tnfsf11* KO mice, were able to support long-term osteoblast survival and to induce TRAcP activity in tibia sections, suggesting that our sRANKL could enter the circulation and reach the skeleton. In our best implant conditions, we also observed an increase of *tnfsf11* KO mouse body weight over untreated controls, suggesting an improvement of somatic growth. Control *tnfsf11* KO mice were instead completely negative to the histochemical detection of TRAcP, showed severe growth retardation and, with a few exceptions, died within the 50th day of life. Most interestingly, in our experimental conditions, we noted the appearance of TRAcP-positive cells on bone surface morphologically and functionally resembling mature osteoclasts. We believe that these results provide a strong background for future studies aimed at addressing the curative effect of the in vivo implants of RANKL-producing cells into a RANKL-deficient mouse model.

Compared to other experimental therapies, our proposed approach could have several advantages. It could replace pharmacological treatments that over time could cause problems of compliance. In fact, since RANKL is a protein, only parenteral administration can be foreseen for this type of therapy, which for chronic administrations is known to be poorly tolerated by patients. Another problem with the pharmacological treatment is the dosage. Administration of 1 mg/kg sRANKL every 2 days for 5 weeks has already been implemented in RANKL KO mice [@bib27], with good responses and phenotypic improvements, but with incomplete disease rescue. Mice still showed growth retardation and partial recovery of hypocalcemia, while tooth eruption and lymph node genesis remained impaired. Furthermore, in this study, sRANKL overdose was experienced after 3 months of treatment. In fact, while growth retardation, tooth eruption and lymph node genesis were not improved, bone mass was severely decreased below the levels of the wild type littermates, inducing an osteopenic phenotype. Moreover, overstimulation of developing T-cells was observed that could potentially induce self-reactive clones escaping the selection process. Large lymphoid aggregates appeared in lungs and gut, along with hepatization of the lung parenchyma. Lungs presented extensive exudates and their function was severely impaired, probably representing the cause of death of some mice. Consistently, treatment with 2 mg/kg sRANKL resulted in a potent toxic effect, with even larger lymphoid expansion in lungs and death occurring at the 2nd week of treatment. Based on these results, we believe that a biotechnological device containing sRANKL cell sources regulated physiologically, as demonstrated in this study for instance by PTH, could bypass the overdose problems and be more tolerated in long-term treatments. In fact, PTH, which is elevated in osteopetrosis due to the hypocalcemic condition [@bib41; @bib42], could play a central role in the control of RANKL expression in osteoblasts implanted in vivo for therapeutic purposes. It could induce a burst of sRANKL release in the first phase of treatment then, being attenuated by the stabilization of calcemia, it could contribute to a more physiologic release of the cytokine according to the calcemic status of the subject.

The use of diffusion chambers that isolate the implanted cells from the host tissue could represent another advantage compared to traditional cell implants. In fact, while consenting the flow of soluble factors, the durapore membrane prevents the contact of the implanted cells with the host tissue. Although T lymphogenesis is impaired in RANKL KO mice, the reaction to allografts has not been evaluated and it could be a prudent maneuver to isolate implanted cells from the host immune system. Of course, immune response could still occur against the cytokine itself. However, this would be a problem also for pharmacological therapy or for conventional cell transplantation. In the case of RANKL, however, we predict that this is likely not to occur due to the fact that both the animal model of RANKL deficiency [@bib25; @bib26] and patients affected by mutations of the *TNFSF11* gene [@bib18] carry non-functional proteins which could induce immune tolerance, thus preventing immune response to the exogenous intact RANKL.

Finally, we believe that our strategy could be applied also beyond osteopetrosis. In fact, similar devices could be employed for deficiencies of other cytokines. In this case, the prevention of the immune response by isolating the curative cells from the host tissue could be even more important if the disease did not show immune failure.

5. Conclusions {#sec5}
==============

In this work, we have provided the proof-of-principle that diffusion chambers could be used to induce active ectodomain shedding of a membrane-bound cytokine. Indeed, we have demonstrated that the osteoclastogenic cytokine, RANKL, was released by osteoblasts, and that appropriate culture conditions, osteoblast adhesion to 3D HA scaffold and functionalization of scaffold with MMP14 enhanced its shedding making it measurable in conditioned media to a concentration compatible with the induction of osteoclastogenesis. We also demonstrated that, in vivo, sRANKL released through the permeant diffusion chambers entered the circulation and triggered systemic effects, inducing osteoclastogenesis and improving the bone phenotype of *tnfsf11* KO mice. Considering the overdose adverse effects demonstrated for the administration of sRANKL in *tnfsf11* KO mice [@bib27], we believe that our approach could tender the advantage of a "physiologic" regulation according to the hormonal status of the recipient. Our method could therefore open up a new avenue for future experimentation that could influence the treatment of currently incurable diseases, including the osteopetrosis due to RANKL deficiency.
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![Release of sRANKL in conditioned media. (A) ELISA assays were performed to evaluate the concentrations of sRANKL and of the RANKL-decoy receptor osteoprotegerin in conditioned media from osteoblasts cultured for the indicated times, then the free sRANKL concentration was calculated on the basis of a RANKL/OPG 1:1 [m]{.smallcaps} ratio. (B, C) ELISA assays as described in (A) to calculate the free sRANKL concentration in conditioned media from (B) mouse bone marrow (BM) stromal cells and (C) mouse BM mesenchymal stem cells, cultured for 5 days, in comparison with mouse calvarial osteoblasts. (D) Real-time RT-PCR on RNA extracted from primary osteoblast cultures at the indicated times of culture. (E) Western blot analysis of sRANKL released in the osteoblast conditioned media pooled at the indicated times of culture. Numbers below the bands represent the relative arbitrary densitometric units. Data are the mean ± s.d. of three independent experiments. Statistics: unpaired Student\'s *t* test.](gr1){#fig1}

![Culture conditions and RANKL assays. (A) Phase contrast microscopy of mouse calvarial osteoblasts cultured on hydroxyapatite (HA) granulates for 5 days (Bar = 1 mm). (B) Nuclear staining by Hoechst dye (blue) of the same field as in (A) to identify the cells. (C) Phase contrast microscopy of mouse calvarial osteoblasts cultured on 3D HA scaffolds for 5 days (Bar = 1 mm). (D) Nuclear staining by Hoechst dye of the same field as in (C) to identify the cells. Dot line: edge of a HA spicule of the scaffold. (E) ELISA assays as described in [Fig. 1](#fig1){ref-type="fig"}A to calculate the free sRANKL concentration in conditioned media from osteoblasts grown on HA granulates or 3D HA scaffold for 5 days, compared to standard cultures on plastic dishes. (F) Mouse calvarial osteoblasts were cultured for 5 days in standard condition in the presence of vehicle or 10^−8^ [m]{.smallcaps} hrPTH(1-34), given every day for the timeframe of the experiment. ELISA assays as described in [Fig. 1](#fig1){ref-type="fig"}A to calculate the free sRANKL concentration in conditioned media. Data are (A--D) representative or (E, F) the mean ± s.d. of three independent experiments. Statistics: unpaired Student\'s *t* test.](gr2){#fig2}

![Enzymatic treatments. (A) Histochemical evaluation of alkaline phosphatase cytochemical positivity (blue staining) in mouse calvarial osteoblasts treated with the indicated MMP14 concentrations for 5 days (Bar = 1 mm). (B) ELISA assays as described in [Fig. 1](#fig1){ref-type="fig"}A to calculate the free sRANKL concentration in conditioned media from cells treated as described in (A). (C) Mineralization assay by alizarin red in mouse calvarial osteoblasts cultured in osteogenic medium treated with the indicated MMP14 concentration for 5 days (Bar = 1 mm). (D) Stability of the catalytic activity of 50 ng/ml MMP14 analyzed in cell-free condition, in a long-term time-course experiment of degradation of quenched fluorescent peptide 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-\[3(2,4-dinitrophenyl)-L-2,3-diaminopropionyl\]-Ala-Arh-NH~2~ (MCA). Peptide substrate was added at time 0 at concentration of 1 μ[m]{.smallcaps}, then accumulation of the fluorescent product was analyzed up to day 10, when a plateau was reached. At this time, excess peptide substrate (20 μ[m]{.smallcaps}) was added and reaction proceeded up to day 15. Results are the mean ± s.d. of a triplicate experiment. (E) Mouse calvarial osteoblasts were cultured for 5 days with 1 μg/ml of the indicated enzymes, then ELISA assays were performed as described in [Fig. 1](#fig1){ref-type="fig"}A to calculate the free sRANKL concentration in conditioned media. Data are (A, C) representative or (B, D, E) the mean ± s.d. of three independent experiments. Statistics: (B, E), unpaired Student\'s *t* test; (D), one-way ANOVA. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr3){#fig3}

![MMP14 immobilization and osteoclastogenesis assay. (A) MMP14 (1 μg/ml) was adsorbed to GST-agarose (GST-A) beads by overnight incubation at 37 °C with 2.5% of the cross-linker agent glutaraldehyde. The catalytic activity of absorbed MMP14 was protected by pre-incubation for 2 h with 20 or 50 μ[m]{.smallcaps} MCA. MMP14-adsorbed GST-agarose beads were then extensively washed to remove both MCA and glutaraldehyde, and incubated with 1 μ[m]{.smallcaps} MCA for the indicated times at 37 °C. Free (non-adsorbed) MMP14 was used as positive control. (B) Immobilization of MMP14 on 3D HA scaffold, using different concentrations of both glutaraldehyde (Glu) and MMP14, as indicated. Procedures for immobilization were the same described in (A). Free (non-adsorbed) MMP14 was used as positive control. Phosphate Buffer Saline (PBS) was used as negative control. (C) ELISA assay as described in [Fig. 1](#fig1){ref-type="fig"}A to calculate the free sRANKL concentration in conditioned media from mouse calvarial osteoblasts cultured on 3D HA scaffold functionalized with vehicle or with MMP14 as indicated. (D) Ficoll-purified mouse bone marrow osteoclast precursors were incubated for 6 days with 10 ng/ml M-CSF and the indicated concentrations of human recombinant RANKL. At the end of incubation, cells were fixed and stained for the osteoclast-specific marker Tartrate-Resistant Acid Phosphatase (TRAcP). Multinuclear (\>3 nuclei) TRAcP-positive cells were then enumerated and expressed as % of untreated cultures. Average numbers at plateau ranged between 15 and 40 osteoclasts/well (96 multiwell plates). Data are expressed as the mean ± s.d. of three independent experiments. Statistics: (A, B, D), one-way ANOVA; (C), unpaired Student\'s *t* test.](gr4){#fig4}

![In vivo implants of Diffusion Chambers (DC) in young *tnfsf11* knockout (KO) mice. (A) DCs containing primary calvarial osteoblasts implanted in a 1 month-old WT mice and harvested after 3 weeks. Cytochemical staining for the osteoblast-specific marker alkaline phosphatase (Bar = 1 mm). (B) Body weight expressed in grams (gr) of wild type (WT) and *tnfsf11* knockout mice treated with PBS (KO) or implanted at the age of 21 days (arrow) with one DC containing primary calvarial osteoblasts on MMP14-functionalized 3D HA scaffold (KO + DC). (C, D) Histological sections of proximal tibia histochemically stained for the Tartrate-Resistant Acid Phosphatase (TRAcP), showing (C) no TRAcP-positive cells in a non-implanted KO mouse and (D) small TRAcP-positive cells (arrows) in a KO mouse implanted for 1 month with a DC containing primary calvarial osteoblasts on functionalized 3D HA scaffold (Bar = 50 μm). Results are representative (A, C, D) or (B) the mean ± s.d or three mice per group. Statistics: one-way ANOVA. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr5){#fig5}

![In vivo implant of Diffusion Chambers (DC) in adult *tnfsf11* knockout (KO) mice. Body weight expressed in grams (gr) of wild type (WT) mice and *tnfsf11* knockout mice treated with PBS (KO) or implanted with 1 (KO + 1DC), 3 (KO + 3DC) or 4 (KO + 4DC) diffusion chambers containing primary calvarial osteoblasts on MMP14-functionalized 3D HA scaffold. Arrows: time of first (1 or 2 DC) and second (2 DC) implants (B--E) Histological sections of proximal tibias histochemically stained for the Tartrate-Resistant Acid Phosphatase (TRAcP) (arrows) showing TRAcP-positive cells in KO mice implanted with (C) 1, (D) 3 and (E) 4 DCs (Bar = 50 μm). (F) High magnification of a TRAcP-positive osteoclast sitting on bone in histological section of proximal tibia of a KO mouse implanted with 4 DCs in which nuclei (arrows) have been stained with DAPI (Bar = 10 μm). (G) Quantification of the number of osteoclasts/tibia. (H) Quantification of the mean osteoclast area. Results are (B--F) representative or (A, G, H) the mean ± s.d of three mice per group. Statistics: (A) one-way ANOVA; (G, H) unpaired Student\'s *t* test).](gr6){#fig6}

![Bone resorption and trabecular bone structural variable in *tnfsf11* knockout (KO) mice implanted with Diffusion Chambers (DC). (A) Representative osteoclast of a KO mouse implanted with 4 DCs showing Tartrate-Resistant Acid Phosphatase (TRAcP)-positivity (purple staining), multinuclearity (DAPI blue staining) and ability to excavate Howship lacuna (yellow dotted line) (Bar = 10 μm). (B) Quantification of the trabecular bone volume over the total tissue volume (BV/TV) in proximal tibias of WT and KO mice treated with PBS or implanted with 3 or 4 DCs. Results are (A) representative or (B) the mean ± s.d of 3 mice per group. Statistics: unpaired Student\'s *t* test.](gr7){#fig7}

![Lymphoid aggregates in lungs. (A) Histological sections of lungs from WT and *tnfsf11* knockout mice untreated (KO) or subjected to implants of 4 DC total (KO 4DC), stained with hematoxylin/eosin, showing lymphoid aggregates (arrows). (Bar = 100 μm). (B, C) Quantification of (B) number and (C) area of lymphoid aggregates in lungs. Results are (A) representative or (B, C) the mean ± s.d of 3 mice per group. Statistics: unpaired Student\'s *t* test. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr8){#fig8}
